Member Info for CHELSEA7

11.60/12

Agree with that ONW. Will see what CH replies with.

11.60/11.8

24/07/2018 15:03 5,000 11.9

Tosh, I think you are right. Both of you make pertinent points. Shame it has to be a war between you though.

Inanaco, appreciate your posts too, end of the day both of you cant be right.

Hotwings, I was thinking earlier that any plans for further development would have to be approved by CRUK to qualify for the funding. I"m glad boom and ivy picked up on my earlier comments, it is starting to make more sense now and still
is a wonderful bounty to progress Moditope.

Absolutely genuine, there might be a few opinions but just one answer. Again thanks for your input.

Thanks Konar, good to see the BB getting used properly (sort of) again!!

Will definately post up CHs reply, would appreciate anybody elses responses too.

Crumbs, was just thinking the same, lol.

Hotwings, thanks ,for all the crap thats been going on here, surprised it has taken so long to debate this.

Sure not the only one to ask, but will let you know his reply ATB

Dear Cliff,

Thanks for the two recent RNSs re Ichor and the share issue. I guess this was needed before the IND was submitted.

Cliff, could you advise me, how the Grand Challenge prize money is distributed, should we win, please G-d.

Best of luck with everything, you must be very busy.

Sincerely

Paul

Prof. Lindy Durrant, Chief Scientific Officer, Scancell, and Principal Investigator of Project Blueprint, said: "We are thrilled to be on the CRUK Grand Challenge shortlist. This brings us one step closer to delivering our cancer vaccine blueprint. We believe this approach will provide an effective, novel therapy and facilitate the development of a comprehensive strategy of combinatorial cancer treatment for patients with most types of cancer. Our unique academic-biotech-clinical partnership, facilitating access to reagents and clinical trials, positions us for success in this space."

Â

Â

Dr Cliff Holloway, Chief Executive Officer, Scancell, commented:  "We are very excited to be an integral member of the team shortlisted for this prestigious award.  If successful, this significant, non-dilutive funding will allow us to extend the utility of our Moditope® platform to develop a new vaccine, Modi-3, in a range of cancers beyond those targeted by our other Moditope candidates, Modi-1 and Modi-2.  This project also allows our technology to be further validated by an exceptional team of scientists.  Project Blueprint envisages a future in which every cancer patient will be offered, as a standard-of-care, a therapeutic vaccine that is tailored to their genetic and antigenic profile".

Ray, agree with that. Can"t imagine anyone doesn"t.

lol

Deadly, i havent got a problem with a commercial deal this year, believe me, just managing my own expectations.

Interested in distribution of prize money if we win all the same.

Has that been said boom. I was wondering how prize money is to be distributed.

All about expectations deadly. I am not expecting the liquidity event you mention by November this year. On the other hand we know November is the time for GC results. A M/Cap of £46m with £30m in cash and two trials SCIB1/2 paid for, all day long. Just MO.

http://www.lse.co.uk/share-regulatory-news.asp?shareprice=AVCT&ArticleCode=kfvhxe1f&ArticleHeadline=Major_Therapeutics_Codevelopment_Partnership

Up 70% on that!!!!!!!!

Catch yer later, its actually cooler outside than in, lol. Last weeks Ichor RNS produced two trades, 6k buys!!!

£46.35m, lol.

What I would say is for a company with a M/Cap of £46.35 a Grand Challenge win would furnish our cash coffers to about £30m!!! That is some liquidity event.